PVLA vs. MLYS, BHC, IBRX, CPRX, BEAM, TARS, IDYA, BLTE, AGIO, and ETNB
Should you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include Mineralys Therapeutics (MLYS), Bausch Health Cos (BHC), ImmunityBio (IBRX), Catalyst Pharmaceuticals (CPRX), Beam Therapeutics (BEAM), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), Agios Pharmaceuticals (AGIO), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry.
Palvella Therapeutics vs. Its Competitors
Palvella Therapeutics (NASDAQ:PVLA) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 20.5% of Palvella Therapeutics shares are held by company insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Palvella Therapeutics' return on equity of -62.30% beat Mineralys Therapeutics' return on equity.
Palvella Therapeutics has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.
In the previous week, Palvella Therapeutics had 8 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 14 mentions for Palvella Therapeutics and 6 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.85 beat Palvella Therapeutics' score of 0.48 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.
Palvella Therapeutics currently has a consensus price target of $69.27, suggesting a potential upside of 10.61%. Mineralys Therapeutics has a consensus price target of $43.50, suggesting a potential upside of 7.51%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Palvella Therapeutics is more favorable than Mineralys Therapeutics.
Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Palvella Therapeutics beats Mineralys Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Palvella Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palvella Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PVLA) was last updated on 10/3/2025 by MarketBeat.com Staff
